Glow 70 mg Multi-Peptide Injection Pen

GLOW 70 mg Multi-Peptide Pen

GLOW 70 mg Multi-Peptide Multi-Dose Pen

A pre-filled multi-peptide formulation containing a combined 70 mg peptide blend consisting of GHK-CU, BPC-157 and TB-500.

Product Composition

• GHK-CU: 50 mg
• BPC-157: 10 mg
• TB-500: 10 mg
• Total peptide content: 70 mg
• Total solution volume: 5 mL
• Concentration: 14 mg / 0.6 mL
• Format: Pre-filled multi-dose pen

About the GLOW Blend

GLOW combines three peptides that are commonly discussed in scientific and preclinical research surrounding cellular processes, tissue biology and recovery-related mechanisms.

GHK-CU is a copper-binding peptide that has been investigated in relation to skin biology, extracellular-matrix processes, collagen-related pathways and cellular signalling.

BPC-157 is an experimental peptide that has been investigated primarily in preclinical research examining tissue and gastrointestinal biology. Human evidence remains limited, and research findings should not be interpreted as established therapeutic effects.

TB-500 is associated with research into thymosin-beta-4-related mechanisms, including cellular migration, angiogenesis and tissue-repair pathways.

Research Areas

The combined ingredients are researched in areas including:

• Skin and connective-tissue biology
• Collagen-related processes
• Extracellular-matrix research
• Cellular signalling
• Tissue-repair mechanisms
• Cell migration
• Regeneration and recovery pathways
• Inflammation-related research
• Wound-healing mechanisms
• Research into tissue integrity and cellular recovery

These areas represent subjects of scientific investigation rather than guaranteed outcomes from the finished product.

Product Format

The GLOW formulation is supplied in a pre-filled multi-dose pen, providing a convenient research format without requiring preparation of a powder formulation.

Storage

• Store refrigerated at 2–8°C.
• Do not freeze.
• Protect from sunlight.
• Keep the pen capped when not in use.
• Keep securely stored and away from children.

The FDA has specifically noted that injectable GHK-Cu and BPC-157 products can present concerns relating to peptide impurities, aggregation and limited human safety data, so this product should be treated strictly within an appropriate research framework.

For Research Purposes Only.